1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 01023010 / TOP-003, NCT00284258
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Other
Protocol IDs: JACCRO GC-05, NCT00639327
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Other
Protocol IDs: KYUH-UHA-GC04-03, NCT00182611
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Other
Protocol IDs: JCOG9912, C000000062, NCT00142350
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 to 80
Sponsor: Other
Protocol IDs: HKIT-GC, NCT00216034
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SC101, NCT00202969
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 to 77
Sponsor: Other
Protocol IDs: ISO/5FU-10, NCT00195572
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 to 79
Sponsor: Other
Protocol IDs: JACCRO GC-03, NCT00287768
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Temporarily closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: HGCSG0601, IFOX study, NCT00316745
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 to 75
Sponsor: Other
Protocol IDs: YCU-BRI-HN-05-01, NCT00336947
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 01023017, NCT00498225
|
|
12.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 to 80
Sponsor: Other
Protocol IDs: TMDU-TRICC0706, TRICC0706, NCT00660894
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 to 80
Sponsor: Other
Protocol IDs: TMOG-GC01, NCT00687843
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10020380, NCT00770874
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TPU S-1301, TAIHO-TPU-S1301, QUINT-TPU-S1301, NCT00400179
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 74
Sponsor: Other
Protocol IDs: AMC0901, NCT00915382
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TPU-S1101; ID02-694, NCT00072787
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 76 to 80
Sponsor: Other
Protocol IDs: HGCSG0502, DS-Elderly, NCT00209729
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 20 to 75
Sponsor: Other
Protocol IDs: HGCSG0405, GEMS-1, NCT00209677
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 20 to 74
Sponsor: Other
Protocol IDs: SCC-07-01, NCT00524706
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2006-01-024, NCT00531245
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMS-MKA0201, NCT00681252
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 20 to 85
Sponsor: Other
Protocol IDs: IMS-MKA2402, NCT00681577
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EORTC-16972C/G, TAIHO-EORTC-16972C/G
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: KYUH-UHA-GC03-01, NCT00088816
|
Mobile | Español
